Newspaper icon
The latest issue of Financial Standard now available as an e-newspaper
READ NOW

Financial Planning

BT Financial scraps opt-out cover

MICHAEL HOBBS  |  TUESDAY, 18 MAR 2008
BT Financial Group has withdrawn its planned integration of an 'opt-out' insurance cover across its corporate and personal super products after negative member feedback.

Bear Stearns a 'reasonable risk': JPMorgan

JPMorgan Chase chief executive and chairman Jamie Dimon has said that the group is taking reasonable risk and have built in an appropriate margin for error in the proposed acquisition of Bear Stearns.

ING Aus appoints new chief

A new chief executive, a new $50 million program and a new profit record are all in a day's work for ING Australia.

FPA to offer Life Risk course

The Financial Planning Association is to provide accreditation in speciality professional areas, with the Life Risk Advisers program the first off the rank.

Austock teams with Cantor

When financial services group Austock Group decided to look for a partner in the US, it went all the way to the top when it signed an alliance with financial services giant Cantor Fitzgerald.

Suncorp/Tyndall shifts to enhanced indexing

Just more than three months after Suncorp/Tyndall's Australian equities team left to set up a boutique, the group has signed up Russell's transition management team to run its $3 billion-plus equities portfolio under a new enhanced indexing model.

Diversity wins at State Street

RUTH LIEW  |  THURSDAY, 13 MAR 2008
State Street Global Advisors (SSgA), the investment management arm of State Street Corporation, is to launch a range of diversified growth strategies using both traditional and alternative asset classes.

High net worth, high expectations

MICHAEL HOBBS  |  THURSDAY, 13 MAR 2008
As much as providing planning services to high net worth clients is a surefire way to grow funds under advice (FUA), gaining their loyalty is as hard as it looks.

Value after sub-prime: van Eyk

MICHAEL HOBBS  |  THURSDAY, 13 MAR 2008
Investors should be looking to invest in emerging markets and shares that benefit from market volatility in the coming year, according to Stephen van Eyk, van Eyk Research managing director.

Local biotech shines through overseas listing

RUTH LIEW  |  THURSDAY, 13 MAR 2008
ASX-listed biotechnology firm Starpharma may not have flagged much interest from local investors, but the company has attracted the attention of US funds.